Deuterated Defactinib compound and use thereof
AssigneeHinova Pharmaceuticals Inc.
InventorsWu Du, Yu Li, Kun Wen, Xinghai Li, Yuanwei Chen
Life of this patent
Estimating the term…
Abstract
This disclosure provides a compound as shown in formula (I) or optical isomers, pharmaceutically acceptable salts, hydrates or solvates thereof. In formula (I), R1-R18 are independently selected from hydrogen and deuterium respectively, but not all are hydrogen at the same time. The compound and salts, hydrates or solvates thereof can be used as FAK inhibitors, and used in the preparation of anti-cancer drugs, and compared with the undeuterated control compound Defactinib, the compound has significantly improved metabolic stability and pharmacokinetic properties.
Claims12
A compound of formula (I) or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof:
- wherein, R1-R18 are each independently selected from hydrogen and deuterium, with the proviso that not all of them are hydrogen at the same time.
Dependencies are inferred from the claim text.